U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT06930703) titled 'Cannabidiol in Sickle Cell Disease' on April 09.
Brief Summary: Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Sickle Cell Disease
Intervention:
DRUG: Cannabidiol
Cannabidiol (CBD) twice daily taken orally for 4-weeks
DRUG: Placebo
Placebo equivalent twice daily taken orally for 4-weeks
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Icahn School of Medicine at Mount Sinai
Information provided by (Responsible Party): Susanna Cu...